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Abstract
Background: Accurate staging of rectal tumors is essential for making the correct treatment
choice. In a previous study, we found that loss of 17p, 18q and gain of 8q, 13q and 20q could
distinguish adenoma from carcinoma tissue and that gain of 1q was related to lymph node
metastasis. In order to find markers for tumor staging, we searched for candidate genes on these
specific chromosomes.
Methods: We performed gene expression microarray analysis on 79 rectal tumors and integrated
these data with genomic data from the same sample series. We performed supervised analysis to
find candidate genes on affected chromosomes and validated the results with qRT-PCR and
immunohistochemistry.
Results:  Integration of gene expression and chromosomal instability data revealed similarity
between these two data types. Supervised analysis identified up-regulation of EFNA1 in cases with
1q gain, and EFNA1 expression was correlated with the expression of a target gene (VEGF). The
BOP1 gene, involved in ribosome biogenesis and related to chromosomal instability, was over-
expressed in cases with 8q gain. SMAD2 was the most down-regulated gene on 18q, and on 20q,
STMN3 and TGIF2 were highly up-regulated. Immunohistochemistry for SMAD4 correlated with
SMAD2 gene expression and 18q loss.
Conclusion: On basis of integrative analysis this study identified one well known CRC gene
(SMAD2) and several other genes (EFNA1, BOP1, TGIF2 and STMN3) that possibly could be used for
rectal cancer characterization.
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Background
Accurate staging of rectal tumors is essential for choosing
the correct treatment. Small pedunculated adenomas can
be removed by snare excision, while large sessile adeno-
mas can be cured by transanal endoscopic microsurgery
[1]. For carcinomas, total mesorectal excision with preop-
erative radiotherapy is the gold standard [2]. However,
preoperative staging using histology and modern imaging
techniques is not always adequate, resulting in either
under- or over-treatment. Therefore in current practice,
additional markers indicating the aggressiveness of the
tumor to be resected are extensively investigated [3,4]. It is
of utmost importance to have parameters that can dis-
criminate large benign adenomas from adenomas with a
small invasive focus, as well as carcinomas with and with-
out lymph node metastasis.
Recently, studies have investigated the application of
microarrays in the diagnosis and prognosis of various
stages of colorectal cancer (CRC). Gene expression signa-
tures have been published that discriminate adenomas
from carcinomas, Dukes B and C CRC, as well as lymph
node positive and negative CRC patients [5-8]. Other
studies using array comparative genomic hybridization
(aCGH) describe specific genomic alterations related to
different stages of colorectal cancer [9-12]. While there is
little overlap between gene lists obtained from expression
studies, common genomic alterations involved in CRC
progression are established [13,14]. Chromosome 8q,
13q, and 20 gain occur early in the establishment of pri-
mary CRCs, loss of 4p is associated with the transition
from Dukes' A to B-D. Deletion of 8p and gains of 7p and
17q are correlated with the transition from primary tumor
to liver metastasis, whereas losses of 14q and gains of 1q,
11, 12p, and 19 are late events (reviewed in [14]).
Several studies have previously integrated gene expression
profiles and genomic alterations in CRC and found a
good correlation between both data types [15-19]. Tsafrir
et al. [19] found that often, large chromosomal segments,
containing multiple genes, are transcriptionally affected
in a coordinated way, and suggested that the underlying
mechanism is a corresponding change in DNA content.
Furthermore, they showed that these aberrations are
absent in normal colon mucosa, appear in benign adeno-
mas, become more frequent as disease advances, and are
found in the majority of metastatic samples. In contrast,
Platzer et al. found that underexpression was more com-
mon than overexpression in amplified regions[20], and a
study by Staub et al. found that deleted regions usually
show underexpression while amplified regions exhibit
heterogenous expression. For several gene islands of
deregulated expression chromosomal aberrations have
never been observed [18].
While those studies mainly analyzed how chromosomal
aneuploidies affect global gene expression, we used an
integrative approach to identify specific candidate genes
for staging rectal tumors. In a previous study, we showed
that loss of 17p, 18q12-22 and gain of 8q22-24,13q and
20q could accurately distinguish adenoma from carci-
noma tissue, and that gain of 1q23 was correlated to
lymph node metastasis [21]. In the present study, we
identify target genes on the affected chromosomes and
validate the microarray data by means of quantitative RT-
PCR and immunohistochemistry. We believe that this
integrative approach generates more accurate and robust
data than either data type alone.
Methods
Samples
Sixty-six fresh-frozen operated tumor samples were
derived from a previous study in which copy number
aberrations were determined [21]. In addition, material
from 13 other cases was obtained. The samples were from
patients treated by TEM from the IJsselland Hospital and
Reinier de Graaf Hospital, the Netherlands, or from the
TME trial, a Dutch multicenter trial in which 1530
patients were included from 1996 to 1999 [2]. None of
the patients received radiotherapy or other adjuvant ther-
apy. All samples were reviewed by a pathologist (H.M.),
dysplasia was scored, and tumor percentage was assessed
(50–80%) in a frozen section of the tissue. Intramucosal
carcinomas were considered as adenoma with high grade
dysplasia, as opposed to invasive carcinoma [22]. The
local medical ethical committee approved the study (pro-
tocol number P04.124).
RNA isolation
Tumors were macrodissected in a cryostat by removing
surrounding non-neoplastic tissue. Twenty 30-μm sec-
tions were cut from each tumor. To guide microdissection,
a 4-μm section was cut and haematoxylin and eosin
stained, before the first section, and after the tenth and
twentieth section, and assessed for the presence of ade-
noma or carcinoma tissue, or a mixture of both. RNA was
isolated with RNAzol reagent (Tel-Test Inc., Friendswood,
TX) according to the manufacturer's protocol and was
purified using the Qiagen RNeasy mini kit with on-col-
umn DNase digestion, according to manufacturer's
instructions (Qiagen Sciences, Germantown, MD). The
quality of the RNA was assessed with lab-on-a-chip using
the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, California).
Microarray analysis
Two μg of total RNA was amplified and labeled using
Ambion's Amino Allyl MessageAmp™ aRNA kit and pro-
tocol (Ambion Inc., Austin, TX). The quality of each aRNA
was checked by lab-on-a-chip (Agilent Technologies). DyeBMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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incorporation was checked with a Nanodrop (Wilming-
ton, DE). For each microarray experiment, 2.0-μg aliquots
of aRNA were labeled with Cy5 (Amersham Biosciences,
Buckinghamshire, UK). The labeled aRNAs were mixed
with equal amounts of Cy3-labeled reference aRNA, con-
sisting of pooled RNAs isolated from five colorectal cancer
cell lines (HCT116, LS411N, SW480, HCT15, Caco2) and
five normal rectum samples. To the mixture of labeled ref-
erence and sample RNA, 20 μg human COT-1 DNA (Inv-
itrogen, Carlsbad, CA), 8 μg yeast tRNA (Invitrogen) and
20 μg polyadenylic acid (Sigma-Aldrich, St. Louis, MO)
were added. Preheated hybridization buffer (25% forma-
mide, 5 × SSC, 0.1% SDS) was added just before overnight
hybridization at 42°C to human 35 K oligo microarrays,
manufactured at the Central Microarray Facility (CMF) of
the Netherlands Cancer Institute. Protocols, GeneID list
and information about arrays are available at the website
of the CMF http://microarrays.nki.nl. Hybridization slides
were washed and scanned using the Agilent G2565BA
Microarray Scanner (Agilent Technologies); spot intensi-
ties were extracted from the scanned images with Genepix
5.1 (Axon, Baden, Switzerland).
Data analysis
Raw intensity data (.gpr files) were analyzed in the R envi-
ronment http://www.r-project.org. The Limma (linear
models for microarray data) package of Bioconductor
http://www.bioconductor.org was used for importing the
data, normalizing the arrays and identifying differentially
expressed genes. Control spots and spots with more than
10% saturation, a diameter smaller than 60 μm or signal
intensity less than 20 counts above background were
excluded from the analysis. Data were corrected for local
background (method normexp) and normalized within
arrays by print-tip loess normalization and between arrays
by quantile normalization. Duplicate experiments were
performed for eight different tumor samples, showing
Pearson correlation coefficients ranging from 0.92 to
0.97.
Statistically significant differences in gene expression were
assessed using a moderate empirical Bayes test statistic
available through Limma. The B-value is the log-odds that
a gene is differentially expressed. The obtained p-values
were controlled for false discovery using the Benjamini
and Hochberg procedure. Oligos with corrected p-values ≤
0.001 were considered statistically significant.
In the integrated analysis, the gene expression levels were
normalized per gene by subtracting the average gene
expression of a reference sample set consisting of the ade-
nomas with a limited amount of genomic changes (maxi-
mum of two small aberrations). Chromosomal plots of
expression values were made in R by smoothing and inte-
grated analysis [21,23]. Heat maps of expression data of
specific chromosomes were generated in Spotfire Deci-
sionSite (Spotfire, Sommerville, MA). For supervised anal-
ysis, we used Statistical Analyses of Microarrays (SAM)
[24]. We analyzed every affected chromosome arm sepa-
rately in SAM to find specific genes related to that specific
chromosomal alteration. Groups were made on the basis
of loss or gain and retention of a specific chromosome,
determined by SNP array analysis [21]. For the analysis of
gene expression levels of individual samples of newly
identified and well-known colorectal cancer genes t-tests
were performed using SPSS 12.0 (SPSS Inc, Chicago, IL,
USA).
The data discussed in this publication have been depos-
ited in NCBIs Gene Expression Omnibus (GEO) http://
www.ncbi.nlm.nih.gov/geo/. The genomic data from the
SNP arrays are accessible through GEO Series accession
number GSE7946, while the gene expression array data
are accessible through GEO Series accession number
GSE12225.
Quantitative RT-PCR (qPCR)
Two micrograms of total RNA was reverse-transcribed
with AMV Reverse Transcriptase (Roche, Penzberg, Ger-
many). Real-time reverse transcriptase (RT) PCR was car-
ried out in an 7900 HT Real Time PCR System (PE Applied
Biosystems, Foster City, CA) in a 10 μl volume containing
1× qPCR SYBR Green/ROX PCR Mastermix (SuperArray,
Frederick, MD) and 1 μl RT2 primer set using the following
PCR profile: 10 minutes at 95°C, followed by 40 cycles of
15 seconds at 95°C and 1 minute at 60°C. Primers used
for real-time RT-PCR were targeted against SMAD2, VEGF,
EFNA1, BOP1, and STMN3. Primer sequences for the tar-
get gene SMAD2 were 5'-ATTTGCTGCTCTTCTGGCTCAG-
3' and 5'-ACTTGTTACCGTCTGCCTTCG-3' and for VEGF
5'-AAACCCTGAGGGAGGCTCC-3' and 5'-TACTTGCA-
GATGTGACAAGCCG-3'; for EFNA1, BOP1, and STMN3,
we used RT2 PCR Primer sets (SuperArray, Frederick, MD).
Candidate genes for normalization were selected on the
basis of showing the least variation between all samples
(CPSF6, GAPDH and  EEF1A). In all 79 samples the
expression of these three genes was measured. Normaliza-
tion was based on geometric averaging of the candidate
normalization genes, as previously described [25], to
acquire a reliable normalization of the qPCR experiments.
This method provides a normalization factor (NF), repre-
sentative of the amount of mRNA in each sample. Subse-
quently the expression of the gene of interest was divided
by this normalization factor. The obtained normalized
expression data were log2 transformed and analyzed in
SPSS 12.0 (SPSS Inc, Chicago, IL, USA).
Immunohistochemistry
BOP1 staining was performed on 4 μm thick fresh frozen
tumor sections, using standard procedures. SMAD4 stain-BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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ing was performed on tissue micro-arrays (TMA), as previ-
ously described [26]. For the formalin fixed paraffin
embedded tissue antigen retrieval was performed by boil-
ing the slides for 10 min in Tris-EDTA pH 8.0 (SMAD4)
using a microwave oven, after which the sections were
cooled in this buffer for at least 2 h at room temperature.
TMA sections were then rinsed in demineralized water
and phosphate buffered saline (PBS). The frozen tissue
sections were incubated for one hour with a 1:100 dilu-
tion of BOP1 cell supernatant (Ascension, Munich, Ger-
many) and the TMA sections with SMAD4 (clone B-8, sc-
7966, Santa Cruz Biotechnology, Santa Cruz, CA; dilution
1:100). Sections were washed in PBS and incubated with
biotinylated rabbit anti-rat (1:200; DAKO, Glostrup, Den-
mark) and streptavidin-biotin complex (1:100; DAKO)
(BOP1) or Envision HRP-ChemMate kit (DAKO)
(SMAD4) for 30 min. Diaminobenzidine tetrahydrochlo-
ride was used as a chromogen for BOP1 staining. All
tumor specimens were stained simultaneously to avoid
interassay variation. BOP1 staining was categorized as no
expression (IHC-score 0), weak expression (1), moderate
expression (2) and strong expression (3). SMAD4 was
scored in the following categories: no nuclear staining
with a positive internal control (total loss) (0), weak
nuclear staining (down regulation) (1), and moderate to
strong nuclear staining (positive) (2, 3). The mean expres-
sion of three punches per patient was assessed for SMAD4.
Results and discussion
Sample description
In a previous study, we built a rectal cancer progression
model based on five "malignant" genomic alterations
(loss of chromosomes 17p and 18q12-22 and gain of
chromosomes 8q22-24, 13q, and 20q) [21]. In addition,
gain of 1q23 was associated with lymph node metastasis.
We assumed that integrating genomic and gene expres-
sion data would allow the identification of important
genes for rectal tumor staging. Therefore, we obtained
gene expression profiles from 66 samples, which were
also typed for LOH and copy number abnormalities in the
previous study [21]. From 13 additional samples, only
gene expression measurements were available. Adenoma
tissue was subdivided into pure adenomas (A/A) and ade-
noma fractions from cases with a carcinoma focus (A/C).
The carcinoma tissue was subdivided into tumor fractions
consisting of a mixture of adenoma and carcinoma tissue
(AC/C), carcinomas without lymph node metastasis (C/
C) and carcinomas with lymph node metastasis (C/C
(N+)). Sample characteristics and genomic data are sum-
marized in Table 1.
Global analysis of gene expression and genomic data
First, we performed a global analysis of the similarity
between gene expression and genomic data as a verifica-
tion of the data. We determined if gene expression
changes between tumor stages were also differently regu-
lated on the chromosomal level. Analysis of the chromo-
somal location of 2853 genes that showed a trend in
expression over the subsequent tumor stages (A/A- A/C-
AC/C- C/C- C/C(N+)) ("progression genes", Additional
file 1) revealed that genes on chromosome 18q were most
frequently down-regulated and genes on chromosome
20q were most frequently up-regulated (Figure 1A), which
was expected based on our genomic data [21]. Heat maps
of gene expression patterns for particular chromosomes
were made. A representative heat map for all the genes on
chromosomes 18q showed that samples with 18q loss
had a lower gene expression than samples with 18q reten-
tion (Figure 1B). Also concordance in individual samples
was seen: gene expression data was plotted along the chro-
mosome and compared to the patterns obtained by the
genomic arrays (Figure 1C). Although the patterns are not
exactly similar, for many chromosomes a clear resem-
blance is observed.
As verification we also determined if gene expression lev-
els of newly identified genes from the progression analysis
and well-known colorectal cancer gene sets were also dif-
ferently regulated on the chromosome level. We focused
on the genes on chromosome 1q, 8q, 13q, 17p, 18q and
20q. We compared gene expression values for the samples
with gain or loss of the respective chromosome versus the
samples with retention. The progression genes on chro-
mosomes 1, 8, 13, and 20 respectively, show a higher
expression in the samples with gain, while genes on chro-
mosome 18 show a lower expression in the samples with
18q loss (Additional files 1 and 2). Some of the colorectal
cancer genes show a significant change in the same direc-
tion as the chromosomal change (e.g. SMAD4, MUC1,
BCL2) while for others this is not evident (i.e. p53, BMP7).
It is worth mentioning that for several of these well known
colorectal cancer genes possible differential expression
cannot be detected since their expression level is too low
on the microarrays.
Further identification of potential candidate genes in 
altered genomic regions
To identify specific genes of pathologic relevance in the
affected chromosomal regions, we performed supervised
analysis using the Significance Analysis of Microarrays
package [24], with groups based on the specific chromo-
somal alterations. This analysis was done for the five
"malignant" chromosomes and 1q. We examined whole
chromosome arms as many patients had lost the whole
arm. With a minimal fold change of 1.5 and a false discov-
ery rate (FDR) <10%, we identified, respectively, 39, 30,
38, 20, 36, and 32 significant genes in relation to 1q gain,
8q gain, 13q gain, 17p loss, 18q loss and 20q gain (Addi-
tional file 1). All expression changes were in the expected
direction, with the gain of 8q as an exception, showingBMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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not only 30 up-regulated genes, but also 3 genes that were
down-regulated. The genes on chromosome 20q had the
highest fold change.
We next focused on four genes identified in the supervised
analyses. EFNA1 on 1q, BOP1 on 8q, SMAD2 on 18q and
STMN3  on 20q, were selected, based on a high fold
change and a low false discovery rate (Additional file 1).
These genes were in the specific listed regions (SMAD2 at
18q21, BOP1 at 8q24), with an exception for 1q, as most
tumors with gene expression values had lost chromosome
1q entirely. Moreover, these genes were previously shown
to be involved in (colorectal) cancer [27-30]. qPCR and
immunohistochemistry were used to validate their expres-
sion in individual cases.
Validation by qPCR
To confirm the association between chromosomal aberra-
tions and specific genes, we performed validation of
expression data by qPCR. Correlation coefficients
between expression array data and qPCR data were 0.71,
0.49, 0.81 and 0.91 (p < 0.001, for all four genes) for
EFNA1, BOP1, SMAD2 and STMN3, respectively. Addi-
tionally the relation between specific genes and genomic
regions was validated: SMAD2 was less expressed in the
samples with 18q genomic loss (p < 0.001), while EFNA1,
BOP1 and STMN3 were all more expressed in samples
with gains of 1q, 8q and 20q, respectively (p = 0.001, p =
0.009 and p < 0.001) (Figure 2). When the different sam-
ple groups were compared for expression of these four
genes, their pattern of expression accompanied the
genomic alterations: SMAD2 was less expressed in the car-
cinomas, while EFNA1, BOP1 and STMN3 all showed an
increased expression in the malignant tumor fractions;
EFNA1 was also notably expressed in the A/C fractions
(Figure 3). The chromosomal changes and accompanying
gene expression changes show thus a good trend with the
increasing malignancy of the tumor stages.
Table 1: Summary of clinical and pathological data of 79 tumor samples
A/A A/C AC/C C/C C/C(N+)
Tissue fraction analyzed Adenoma Adenoma Adenoma and carcinoma mixture Carcinoma Carcinoma
Tumor stage Adenoma Carcinoma Carcinoma Carcinoma Carcinoma
Treatment
TEM 24 6 5 3 1
TME 4 3 2 20 11
Sex (M/F) 15/13 2/7 3/4 10/13 10/2





T1 7 3 11
T2 2 3 12 12
T3 1
Size(cm) (mean) 5.9 4.4 4.2 3.2 5.1
Genomic data
Samples typed(n) 21 8 7 19 11
Abberations (%)
1q23 gain 0 9 11 14 62
8q22-24 gain 9 18 44 50 62
13q gain 4 36 67 59 85
17p loss 17 18 44 91 62
18q12-22 loss 17 36 56 86 77
20q gain 17 27 78 86 92BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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Visual depiction of the similarity between gene expression and genomic data Figure 1
Visual depiction of the similarity between gene expression and genomic data. A. Summary of gene expression data 
for all 79 samples. The distribution of 2853 progression genes over the chromosome arms is shown. The x-axis shows all chro-
mosome arms, the y-axis shows the percentage of genes for a certain chromosome arm that is differentially expressed. White 
bars represent downregulated genes, black bars represent upregulated genes. B. Heat map of all gene expression data for the 
66 samples with 18q genomic data available. Every column represents a single sample. Samples on the left side show loss of 
18q, while samples on the right side show retention of chromosome 18q, both measured by SNP arrays. The y-axis shows all 
18q genes from the centromere to telomere. Red lines indicate genes with a higher expression, green lines a lower expression. 
C. Chromosomal plot of sample 203 (carcinoma with lymph node metastasis) based on SNP array data (red) and gene expres-
sion array data (green).BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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1q gain and EFNA1
Previously, we found that gain of 1q might be related to
lymph node metastasis in rectal cancer [21]. Samples with
gain of 1q showed a higher expression of two probes for
EFNA1 than samples with 1q retention (Additional file 1
and Figure 2). EFNA1 is a ligand for Eph receptor tyrosine
kinases and plays a key role in the migration and adhesion
of cells during development [31]. Recently, it was found
to be related to tumor-induced neovascularization [27].
Brantley-Sieders et al. found that EFNA1 over-expression
elevated vascular endothelial growth factor (VEGF) levels,
suggesting that EFNA1-mediated modulation of the VEGF
pathway is a mechanism by which EFNA1 regulates ang-
iogenesis [32]. VEGF plays a key role in angiogenesis dur-
ing tumor growth and metastasis [33]. We measured
VEGF mRNA expression by qPCR and found that it was
correlated with EFNA1 mRNA expression (r = 0.353, p =
0.002) (Figure 4). EFNA1 and VEGF showed increased
expression in the carcinomas in comparison to adenomas.
This was expected, as neo-angiogenesis is an important
factor in malignant transformation. However, in lymph
node positive carcinomas VEGF expression appears to be
down-regulated as compared to node negative rectal can-
cers whereas such a trend is not observed for EFNA1. An
explanation for this observation does not seem obvious.
As discussed, the contribution of stromal cells to the
tumor cell gene expression profile seems small [34]. A
possible increase in stromal content cannot provide an
explanation for this result. The effect at the protein level
should also be assessed. Furthermore an alternative might
Validation of array data by RT-PCR Figure 2
Validation of array data by RT-PCR. Plots of relative gene expression (log2 values) measured with RT-PCR are shown. 
The x-axis shows the samples, the y-axis shows the log2 relative gene expression value. Samples with retention are compared 
with samples with loss (18q) or gain (1q, 8q and 20q) of a specific chromosome arm. The line indicates the mean. P-values were 
computed by Student's t-test.BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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be experimental bias due to the small sample size of node
positive rectal cancer cases.
8q gain and BOP1
Gain of chromosome 8q and a higher expression of BOP1
were both observed in most carcinomas (Figure 2). BOP1
is a member of the Pes1-Bop1 complex, involved in ribos-
ome biogenesis [35]. Killian et al. proposed that BOP1
deregulation leads to altered chromosome segmentation
and chromosomal instability in colorectal cancer [29].
They showed that BOP1 copy number increase was associ-
ated with BOP1  gene over-expression, in concordance
with our results. BOP1 is located on 8q24, close to the
MYC oncogene. However, gene dosage increase of BOP1
was independent from that of MYC and was more fre-
quent than MYC over-expression, suggesting that BOP1
over-expression may be one of the main oncogenic conse-
quences of 8q24 amplification in colorectal cancer. In our
data series, gain of 8q, and consequently BOP1  over
expression, was predominantly observed in cases with
high chromosomal instability.
BOP1 protein expression was measured through immu-
nohistochemistry on rectal tumor tissue slides. Specific
cases with high BOP1  mRNA expression showed very
intense nucleolar BOP1 staining (Figure 5A), but a direct
correlation between both parameters was not established
(Figure 5B). Comparing the mean BOP1 protein expres-
sion between samples with 8q retention and 8q gain
revealed a slight, although not significant, increase in the
samples with gain (1.38 vs 1.16 relative protein expres-
sion) (Figure 5B). Post-transcriptional and post-transla-
tional mechanisms are likely to influence protein
expression, possibly blurring the correlation between
mRNA and protein levels for this gene. In such a case, gene
expression data and immunohistochemistry results must
Expression of EFNA1, BOP1, SMAD2 and STMN3 in the different patient groups Figure 3
Expression of EFNA1, BOP1, SMAD2 and STMN3 in the different patient groups. Plots of relative gene expression 
(log2 values) measured with RT-PCR are shown. The x-axis shows the different sample groups. The y-axis shows the relative 
log2 gene expression data. Lines indicate the means. According to ANOVA analysis, the expression of all genes was significantly 
different between the groups.BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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Correlation of EFNA1 with VEGF expression values Figure 4
Correlation of EFNA1 with VEGF expression values. A. Correlation plot of relative log2 EFNA1 mRNA expression (x-
axis) and relative log2 VEGF mRNA expression (y-axis). B. Relative log2 VEGF expression (y-axis) in the different clinical groups 
(x-axis).BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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BOP1 and SMAD4 immunohistochemical staining Figure 5
BOP1 and SMAD4 immunohistochemical staining. A. Example of BOP1 immunohistochemical staining in two carcino-
mas; the left picture shows a weak expression (IHC score 1), the right picture, a very strong expression (score 3). B. Correla-
tion plot of BOP1 mRNA expression (x-axis) and BOP1 protein expression (y-axis) (left) and BOP1 immunohistochemical 
staining (y-axis) related to 8q gain(x-axis) (right). C. Example of SMAD4 immunohistochemical staining in two carcinomas; the 
left picture shows loss of SMAD4 expression (score 1), the right picture positive expression (score 3). D. Correlation plot of 
SMAD4 gene expression (x-axis) and SMAD 4 protein expression (y-axis) (left) and correlation plot of SMAD2 gene expression 
(x-axis) and SMAD 4 protein expression (right) (y-axis).BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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be considered independently because each can provide
clinically meaningful information [36]. Alternatively, the
difference in gene expression might be too subtle to detect
with immunohistochemistry.
18q loss and SMAD2
SMAD2, SMAD4 and DCC are indicated as the prominent
tumor suppressor genes on 18q [30,37]. We found that
SMAD2 was significantly less expressed in the cases with
18q loss (Figure 2), and SMAD2 and SMAD4 were both
down-regulated in the more advanced tumor stages
(Limma-analysis, data not shown). SMAD proteins medi-
ate TGF-β signaling to regulate cell growth and differenti-
ation [38]. LOH in combination with SMAD4 mutations
is a well studied phenomenon in CRC, and SMAD4 gene
mutations are related to advanced tumor stage [39,40].
Immunohistochemistry was technically not feasible for
SMAD2 but was feasible for SMAD4, which is also located
on chromosome18q21.1. Therefore, we tested whether
SMAD4 protein expression was correlated to SMAD4 and
SMAD2 gene expression, which was indeed the case (r =
0.373 (p = 0.002) and r = 0.405, (p = 0.001)) (Figure 5C,
D).
According to Knudson's "two hit hypothesis", both copies
of a tumor suppressor gene should be deleted by a muta-
tion or allelic loss to reduce protein dosage [41]. In our
study, half of the cases showed physical loss of 18q and
thus deletion of one of the SMAD2 alleles. An additional
hit such as a mutation can then be expected, leading to the
observed reduction in protein expression. However,
mutation analysis for SMAD2 did not reveal any muta-
tions in this sample series (data not shown). In the litera-
ture, mutation rates vary between 0 and 30% for SMAD2
and SMAD4 [37,42]. Recently, Alberici et al. showed hap-
loinsufficiency for the SMAD4 locus in mouse models for
colorectal cancer, giving an explanation for the relatively
low mutation rate observed [43]. Consequently, the loss
of one allele already leads to reduced SMAD4 protein
expression and altered TGF-β signaling. The same princi-
ple might apply to SMAD2 and explain our findings,
where only one copy of 18q is lost and no mutation is
found in the SMAD2 gene, but reduced gene expression is
observed.
Genes on chromosome 20q
Genes on chromosome 20 showed the highest fold
change in expression in comparison with genes on the
other chromosomes (Additional file 1). Two interesting
genes were in the top five overexpressed genes: STMN3
and TGIF2. STMN3 is overexpressed in various human
malignancies and plays a role in regulation of the cell
cycle [28,44]. In oral squamous-cell carcinoma, the over-
expression of STMN3 was correlated with tumor progres-
sion and poor prognosis. Kouzu et al. emphasized the
potential role of STMN3 as a biomarker and therapeutic
target for oral squamous-cell carcinoma [28]. TGIF2 was
shown to interact with TGF-β-activated SMADS and
repress TGF-β responsive transcription [45]. Limma-anal-
ysis revealed that TGIF2 was among the ten most signifi-
cant genes in the adenoma-carcinoma comparison. In
ovarian cancer cell lines, amplification of 20q correlated
strongly with TGIF2 over-expression [46]. A recent study
subtracted a chromosomal instability gene expression
profile from 12 different cancer data sets. This 25 gene set
contained, among others, TGIF2, indicating that this gene
plays a role in chromosomal instability [47].
Conclusion
Several studies have integrated global patterns of gene
expression and genomic data in colorectal cancer, with
divergent results. While some studies reported a direct cor-
relation between gene expression and chromosomal aber-
rations [16,17,19,48], others reported that amplification
does not necessarily lead to expression up-regulation[20].
Similarly, genomic regions with deletions show reduced
expression while amplified regions exhibit heterogeneous
expression [18]. We first determined whether copy
number alterations have an effect on gene expression and
saw that changes in genomic regions and gene expression
are usually in the same direction. We then performed
supervised analysis to find target genes on the affected
chromosomes. We identified one well known CRC gene
(SMAD2) and several other genes (EFNA1, BOP1, TGIF2
and STMN3) that possibly could be used for rectal cancer
characterization. It will be interesting to determine if these
molecules can discriminate benign adenomas from ade-
nomas containing an invasive focus and carcinomas with
lymph node metastasis. To validate the impact of these
genes in rectal carcinogenesis it will be worthwhile to
study them for mRNA expression and at the immunohis-
tochemical level in representative cases with normal, ade-
noma and carcinoma tissue from single patients.
Unfortunately frozen material of all those tumor stadia
was not available for the subjects of this study. Studies in
other cancer types have successfully applied supervised
methods [49,50]. Garraway et al. performed supervised
analysis on cell lines with and without 3p amplifications
and identified MITF as a new melanoma oncogene.
In conclusion, gene expression values in regions with
genomic changes are altered in the same direction. We
analyzed gene expression data in relation to specific chro-
mosomal aberrations involved in the progression from
adenoma to carcinoma. By not focusing directly on tumor
stages, but rather on genomic aberrations related to tumor
stages, we identified several specific genes on altered chro-
mosomes in rectal cancer. Specific genes, identified by
such integration methods, could be of additional value to
further explain rectal tumorigenesis.BMC Cancer 2008, 8:314 http://www.biomedcentral.com/1471-2407/8/314
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